Obstructive sleep apnea is a mechanical problem: the upper airway narrows or closes during sleep, and breathing stops or turns shallow until the brain rouses the sleeper. Tirzepatide does not act on the airway. It lowers body weight, and the trials behind its sleep apnea approval tested whether that is enough to change the breathing.
What FDA approved, and for whom
On December 20, 2024, FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, alongside a reduced-calorie diet and more physical activity [2]. The agency described it as the first drug treatment option for certain patients with the condition.
The current label keeps that wording as a second indication, next to chronic weight management [1]. For sleep apnea it lists maintenance doses of 10 mg or 15 mg once a week, reached by the same 2.5 mg steps used for weight. How that ladder works is covered in tirzepatide dosage.
FDA’s own summary of the mechanism is modest. It states that the improvement in breathing events is likely related to the weight reduction [2].
Who was in SURMOUNT-OSA
SURMOUNT-OSA was two double-blind trials run under one protocol at 60 sites in nine countries [3]. Trial 1 enrolled 234 adults who were not using positive airway pressure (PAP), such as a CPAP machine. Trial 2 enrolled 235 who were, and they paused it for 7 days before each sleep study.
Everyone had an apnea-hypopnea index (AHI) of at least 15 events an hour and a body-mass index of 30 or more. The average AHI at the start was 51.5 in trial 1 and 49.5 in trial 2, which is severe apnea. Mean BMI was 39.1 and 38.7.
The label adds that people with type 2 diabetes were excluded [1]. In both trials, about two in three participants had severe rather than moderate apnea at baseline.
How much the breathing changed
The AHI counts pauses and shallow breaths per hour of sleep. On the maximum tolerated dose for 52 weeks, it fell by 50.7% in trial 1 and 58.7% in trial 2 [3]. On placebo it fell by 3.0% and 2.5%.
−50.7%
AHI change on tirzepatide without PAP, vs −3.0% on placebo (52 weeks, n = 234)
Malhotra 2024
−58.7%
AHI change on tirzepatide in PAP users, vs −2.5% on placebo (52 weeks, n = 235)
Malhotra 2024
72.4%
of PAP users on tirzepatide halved their AHI or better, vs 23.3% on placebo
Malhotra 2024
The trials also counted people who reached a level where PAP may no longer be recommended. That meant an AHI under 5, or an AHI of 5 to 14 with an Epworth sleepiness score of 10 or less [3]. It was reached by 42.2% on tirzepatide against 15.9% on placebo in trial 1, and 50.2% against 14.3% in trial 2.
| Trial 1: no PAP | Trial 2: on PAP | |
|---|---|---|
| Change in AHI, events per hour | −25.3 vs −5.3 | −29.3 vs −5.5 |
| Change in body weight | −17.7% vs −1.6% | −19.6% vs −2.3% |
| Hypoxic burden, % min per hour | −95.2 vs −25.1 | −103.0 vs −41.7 |
| Systolic blood pressure at week 48, mmHg | −9.5 vs −1.8 | −7.6 vs −3.9 |
| Remission or mild apnea without sleepiness | 42.2% vs 15.9% | 50.2% vs 14.3% |
Hypoxic burden measures how deep and how long the drops in blood oxygen were. It fell far more on tirzepatide in both trials [3]. So did high-sensitivity C-reactive protein, a marker of inflammation.
Did people feel better rested?
Pooled across both trials, sleep-related impairment scores improved by 7.5 points on tirzepatide and 3.6 on placebo [3]. Sleep disturbance scores improved by 5.7 against 2.7 points.
Those are real differences on validated questionnaires, but the authors flag a limit. The smallest change that matters to a patient on these two scales has not been established, so the clinical weight of the gain is still open.
Why losing weight changes the breathing
The link between weight and apnea predates any drug. A Wisconsin cohort followed 690 employed adults with two sleep studies 4 years apart [4]. Relative to stable weight, a 10% loss predicted about a 26% fall in AHI (95% CI 18% to 34%).
A 10% gain predicted about a 32% rise, and a 6-fold increase in the odds of developing moderate to severe apnea [4]. That was an observational cohort, not a trial, and it measured association rather than proof of cause.
SURMOUNT-OSA participants lost 16 to 17 percentage points more weight than placebo, well past that 10% mark. A large AHI drop alongside a large weight loss is consistent with FDA’s reading that the weight loss is the likely driver.
Side effects in the sleep apnea trials
Adverse events were reported by 79.8% on tirzepatide and 76.7% on placebo in trial 1, and 83.2% against 72.8% in trial 2 [3]. Most were stomach and bowel effects, mild to moderate, and most common while the dose was being raised.
Serious adverse events affected 7.5% of participants overall, at similar rates in both arms. Two confirmed cases of acute pancreatitis occurred on tirzepatide in trial 2. The label says the adverse reactions resembled those in its weight trials [1], which are laid out in tirzepatide side effects.
For the other weekly GLP-1, the trial side effects are set out in semaglutide side effects.
What this means if you have sleep apnea
The evidence applies to a specific group: adults with obesity and moderate to severe apnea confirmed by a sleep study, without type 2 diabetes. Within that group, a year of weekly injections roughly halved breathing events.
The trials used the approved brand product, so the sleep apnea indication belongs to Zepbound. Other peptides marketed for sleep have far thinner records, as the review of peptides for sleep shows.
To compare online prescribers of tirzepatide, see the weight-loss peptide prescriber rankings. For other sleep options with human studies behind them, start at the sleep goal page.